Cargando…
Non-conventional fotemustine schedule as second-line treatment in recurrent malignant gliomas: Survival across disease and treatment subgroup analysis and review of the literature
Fotemustine (FTM) is a treatment option in recurrent malignant gliomas (MGs) after first-line Stupp treatment. The efficacy and the safety of fractionated FTM schedule proposed by Addeo et al was analysed in the present study in recurrent MGs patients. A retrospective analysis on 40 recurrent MGs pa...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6313958/ https://www.ncbi.nlm.nih.gov/pubmed/30655978 http://dx.doi.org/10.3892/mco.2018.1746 |
_version_ | 1783384049074569216 |
---|---|
author | Prelaj, Arsela Rebuzzi, Sara Elena Grassi, Massimiliano Salvati, Maurizio D'Elia, Alessandro Buttarelli, Francesca Ferrara, Carla Tomao, Silverio Bianco, Vincenzo |
author_facet | Prelaj, Arsela Rebuzzi, Sara Elena Grassi, Massimiliano Salvati, Maurizio D'Elia, Alessandro Buttarelli, Francesca Ferrara, Carla Tomao, Silverio Bianco, Vincenzo |
author_sort | Prelaj, Arsela |
collection | PubMed |
description | Fotemustine (FTM) is a treatment option in recurrent malignant gliomas (MGs) after first-line Stupp treatment. The efficacy and the safety of fractionated FTM schedule proposed by Addeo et al was analysed in the present study in recurrent MGs patients. A retrospective analysis on 40 recurrent MGs patients and second-line fractionated FTM chemotherapy was performed. Response evaluation was assessed using RANO criteria and safety was assessed using CTCAE v.4.03. Subgroup analyses based on MGMT methylation, resurgery and reirradiation were performed. A review of the literature was also performed. The results revealed 5 partial responses (13%) and 19 stable diseases (47%) with a disease-control rate of 60%. Median progression-free survival (PFS) was 4 months, with a PFS of 33% at 6 months and 13% at 1 year. The median overall survival (OS) was 9 months and OS at 6 months was of 55% and at 1 year of 30%. Methylated patients experienced longer mPFS (6 vs. 3 months; p=0.004) and mOS (10 vs. 4 months; p<0.0001) compared with unmethylated patients. Patients treated with reirradiation experienced longer mPFS (5 vs. 3.5 months; p=0.48) and mOS (10 vs. 5 months; p=0.11). No survival benefit with resurgery was observed. Furthermore, the fractioned schedule was well tolerated, only 15% of patients developed severe myelotoxicities. Considering the present findings, fractionated FTM schedule is an efficient second-line option for MGs associated with an acceptable myelotoxicity profile. Additionally, MGMT methylation is associated with improved survival outcomes. However, this study highlights the requirement for further prospective randomized studies on resurgery and reirradiation. |
format | Online Article Text |
id | pubmed-6313958 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | D.A. Spandidos |
record_format | MEDLINE/PubMed |
spelling | pubmed-63139582019-01-17 Non-conventional fotemustine schedule as second-line treatment in recurrent malignant gliomas: Survival across disease and treatment subgroup analysis and review of the literature Prelaj, Arsela Rebuzzi, Sara Elena Grassi, Massimiliano Salvati, Maurizio D'Elia, Alessandro Buttarelli, Francesca Ferrara, Carla Tomao, Silverio Bianco, Vincenzo Mol Clin Oncol Articles Fotemustine (FTM) is a treatment option in recurrent malignant gliomas (MGs) after first-line Stupp treatment. The efficacy and the safety of fractionated FTM schedule proposed by Addeo et al was analysed in the present study in recurrent MGs patients. A retrospective analysis on 40 recurrent MGs patients and second-line fractionated FTM chemotherapy was performed. Response evaluation was assessed using RANO criteria and safety was assessed using CTCAE v.4.03. Subgroup analyses based on MGMT methylation, resurgery and reirradiation were performed. A review of the literature was also performed. The results revealed 5 partial responses (13%) and 19 stable diseases (47%) with a disease-control rate of 60%. Median progression-free survival (PFS) was 4 months, with a PFS of 33% at 6 months and 13% at 1 year. The median overall survival (OS) was 9 months and OS at 6 months was of 55% and at 1 year of 30%. Methylated patients experienced longer mPFS (6 vs. 3 months; p=0.004) and mOS (10 vs. 4 months; p<0.0001) compared with unmethylated patients. Patients treated with reirradiation experienced longer mPFS (5 vs. 3.5 months; p=0.48) and mOS (10 vs. 5 months; p=0.11). No survival benefit with resurgery was observed. Furthermore, the fractioned schedule was well tolerated, only 15% of patients developed severe myelotoxicities. Considering the present findings, fractionated FTM schedule is an efficient second-line option for MGs associated with an acceptable myelotoxicity profile. Additionally, MGMT methylation is associated with improved survival outcomes. However, this study highlights the requirement for further prospective randomized studies on resurgery and reirradiation. D.A. Spandidos 2019-01 2018-10-16 /pmc/articles/PMC6313958/ /pubmed/30655978 http://dx.doi.org/10.3892/mco.2018.1746 Text en Copyright: © Prelaj et al. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. |
spellingShingle | Articles Prelaj, Arsela Rebuzzi, Sara Elena Grassi, Massimiliano Salvati, Maurizio D'Elia, Alessandro Buttarelli, Francesca Ferrara, Carla Tomao, Silverio Bianco, Vincenzo Non-conventional fotemustine schedule as second-line treatment in recurrent malignant gliomas: Survival across disease and treatment subgroup analysis and review of the literature |
title | Non-conventional fotemustine schedule as second-line treatment in recurrent malignant gliomas: Survival across disease and treatment subgroup analysis and review of the literature |
title_full | Non-conventional fotemustine schedule as second-line treatment in recurrent malignant gliomas: Survival across disease and treatment subgroup analysis and review of the literature |
title_fullStr | Non-conventional fotemustine schedule as second-line treatment in recurrent malignant gliomas: Survival across disease and treatment subgroup analysis and review of the literature |
title_full_unstemmed | Non-conventional fotemustine schedule as second-line treatment in recurrent malignant gliomas: Survival across disease and treatment subgroup analysis and review of the literature |
title_short | Non-conventional fotemustine schedule as second-line treatment in recurrent malignant gliomas: Survival across disease and treatment subgroup analysis and review of the literature |
title_sort | non-conventional fotemustine schedule as second-line treatment in recurrent malignant gliomas: survival across disease and treatment subgroup analysis and review of the literature |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6313958/ https://www.ncbi.nlm.nih.gov/pubmed/30655978 http://dx.doi.org/10.3892/mco.2018.1746 |
work_keys_str_mv | AT prelajarsela nonconventionalfotemustinescheduleassecondlinetreatmentinrecurrentmalignantgliomassurvivalacrossdiseaseandtreatmentsubgroupanalysisandreviewoftheliterature AT rebuzzisaraelena nonconventionalfotemustinescheduleassecondlinetreatmentinrecurrentmalignantgliomassurvivalacrossdiseaseandtreatmentsubgroupanalysisandreviewoftheliterature AT grassimassimiliano nonconventionalfotemustinescheduleassecondlinetreatmentinrecurrentmalignantgliomassurvivalacrossdiseaseandtreatmentsubgroupanalysisandreviewoftheliterature AT salvatimaurizio nonconventionalfotemustinescheduleassecondlinetreatmentinrecurrentmalignantgliomassurvivalacrossdiseaseandtreatmentsubgroupanalysisandreviewoftheliterature AT deliaalessandro nonconventionalfotemustinescheduleassecondlinetreatmentinrecurrentmalignantgliomassurvivalacrossdiseaseandtreatmentsubgroupanalysisandreviewoftheliterature AT buttarellifrancesca nonconventionalfotemustinescheduleassecondlinetreatmentinrecurrentmalignantgliomassurvivalacrossdiseaseandtreatmentsubgroupanalysisandreviewoftheliterature AT ferraracarla nonconventionalfotemustinescheduleassecondlinetreatmentinrecurrentmalignantgliomassurvivalacrossdiseaseandtreatmentsubgroupanalysisandreviewoftheliterature AT tomaosilverio nonconventionalfotemustinescheduleassecondlinetreatmentinrecurrentmalignantgliomassurvivalacrossdiseaseandtreatmentsubgroupanalysisandreviewoftheliterature AT biancovincenzo nonconventionalfotemustinescheduleassecondlinetreatmentinrecurrentmalignantgliomassurvivalacrossdiseaseandtreatmentsubgroupanalysisandreviewoftheliterature |